ECC 2013: Late Breaking Clinical Trials: ASPECCT
by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.
by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
Taken from the European Cancer Congress ( ECCO / ESMO / ESTRO ) from the 27th September – 1st October 2013 in Amsterdam.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.
A newly-described immunodeficiency syndrome of neutrophil defects, bone marrow fibrosis, nephromegaly, and life-threatening infections arises from a genetic mutation that impairs movement of proteins within cells, researchers found.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
The drug erythropoietin, often called EPO, is banned from sports because it is believed to enhance an athlete’s performance and give people who use it an unfair advantage… read more.
Probiotics have significantly reduced development of hepatic encephalopathy researchers announced at EASL/International Liver Congress.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
Researchers reported encouraging but preliminary results of gene-based immune therapy in two children with relapsed and refractory acute lymphoblastic leukemia (ALL).
Researchers have found that macrophages that play a key role in the immune response – also help to both produce and eliminate the body’s red blood cells (RBCs)…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.